AHK-Cu (Alanyl-Histidyl-Lysine Copper)

1. Overview

AHK-Cu (alanyl-L-histidyl-L-lysine:copper(II)), designated Copper Tripeptide-3 under INCI nomenclature, is a synthetic copper tripeptide variant that differs from the naturally occurring GHK-Cu (Copper Tripeptide-1) by a single amino acid substitution: alanine replaces glycine at position 1 of the tripeptide sequence [1]. This seemingly minor structural modification -- the addition of a single methyl group to the first amino acid -- produces notably different biological activities, with AHK-Cu demonstrating enhanced specificity for hair follicle stimulation compared to its parent compound [1].

The foundational study on AHK-Cu was published in 2007 by Pyo, Yoo, Won, Lee, Kang, Eun, Cho, and Kim from Seoul National University College of Medicine [1]. This landmark paper in Archives of Pharmacal Research demonstrated that AHK-Cu stimulated the elongation of isolated human hair follicles and the proliferation of dermal papilla cells (DPCs) at remarkably low concentrations ranging from 10^-12 to 10^-9 M (picomolar to nanomolar). The study also revealed that AHK-Cu increased vascular endothelial growth factor (VEGF) production while simultaneously decreasing transforming growth factor-beta1 (TGF-beta1) secretion by dermal fibroblasts -- a dual effect with significant implications for androgenetic alopecia, where elevated TGF-beta1 drives follicle miniaturization [1][9].

While GHK-Cu occurs naturally in human plasma, saliva, and urine with a well-established role in wound healing, collagen synthesis, and gene expression modulation [2][4][5], AHK-Cu was engineered as a synthetic variant specifically optimized for hair growth applications. The substitution of alanine for glycine changes the three-dimensional conformation of the peptide, potentially altering its interactions with cellular receptors and signaling pathways relevant to the hair follicle microenvironment. AHK-Cu is commercially available as a cosmetic ingredient and is incorporated into various topical hair growth and scalp care formulations.

Molecular Weight

Approximately 418 g/mol (with copper)

Free Peptide MW

355.43 g/mol (Ala-His-Lys without copper)

Sequence

L-Ala-L-His-L-Lys + Cu2+

INCI Name

Copper Tripeptide-3

Key Study

Pyo et al. 2007, Archives of Pharmacal Research

Effective Concentration

10^-12 to 10^-9 M (picomolar to nanomolar)

Routes Studied

Topical (serum/lotion); ex vivo and in vitro

FDA Status

Not approved as drug; used as cosmetic ingredient (INCI listed)

Structural Difference from GHK-Cu

Alanine at position 1 replaces glycine

2. Mechanism of Action

AHK-Cu exerts its biological effects through multiple interconnected mechanisms centered on dermal papilla cell biology and the follicular growth environment.

Dermal Papilla Cell Proliferation

The primary mechanism documented in the Pyo et al. (2007) study is direct stimulation of dermal papilla cell (DPC) proliferation [1]. Dermal papilla cells are the specialized mesenchymal cells at the base of the hair follicle that control the hair growth cycle by sending instructive signals to surrounding epithelial cells. The volume and cell number of the dermal papilla directly determine hair follicle size -- larger dermal papillae produce thicker, more robust hair shafts. AHK-Cu stimulated DPC proliferation at concentrations as low as 10^-12 M, suggesting extremely high potency at this target [1].

VEGF Upregulation

AHK-Cu increased production of vascular endothelial growth factor (VEGF) by dermal fibroblasts [1]. VEGF promotes angiogenesis -- the formation of new blood vessels -- around hair follicles. Perifollicular vascularization is critical for supplying nutrients and oxygen to the rapidly dividing cells of the hair bulb during the anagen (growth) phase. This mechanism parallels one of the known pathways through which minoxidil promotes hair growth [8], suggesting potential mechanistic overlap between AHK-Cu and conventional hair loss treatments.

TGF-beta1 Suppression

AHK-Cu decreased the secretion of transforming growth factor-beta1 (TGF-beta1) by dermal fibroblasts [1]. This is particularly significant in the context of androgenetic alopecia (AGA), where androgen-induced TGF-beta1 production by dermal papilla cells is a key mediator of follicle miniaturization and premature catagen entry [9]. In balding scalp tissue, TGF-beta1 levels are elevated compared to non-balding areas, and this cytokine suppresses epithelial cell growth in the hair follicle. By reducing TGF-beta1, AHK-Cu may counteract one of the central pathogenic mechanisms of pattern hair loss.

Anti-Apoptotic Effects

AHK-Cu demonstrated significant anti-apoptotic activity in dermal papilla cells [1]:

• Caspase-3 reduction: 42.7% decrease compared to controls. Caspase-3 is an executioner protease in the apoptotic cascade; its reduction indicates suppression of programmed cell death.
• PARP reduction: 77.5% decrease compared to controls. Poly(ADP-ribose) polymerase (PARP) cleavage is a hallmark of late-stage apoptosis; its dramatic reduction confirms strong anti-apoptotic protection.

These anti-apoptotic effects suggest that AHK-Cu protects dermal papilla cells from premature death, potentially maintaining dermal papilla volume and hair-inducing capacity over time.

Wnt/Beta-Catenin Pathway Activation

Research in the broader copper peptide field has established connections between copper tripeptides and the Wnt/beta-catenin signaling pathway, a master regulator of hair follicle development and cycling [10]. Wnt signaling maintains the hair-inducing activity of dermal papilla cells and promotes the transition from telogen (resting phase) to anagen (growth phase) [10]. In androgenetic alopecia, the Wnt inhibitor Dickkopf-1 (DKK-1) is upregulated in balding dermal papilla cells, contributing to follicle miniaturization [11]. AHK-Cu's stimulation of DPC proliferation and its anti-apoptotic effects are consistent with Wnt pathway activation, though direct molecular evidence specifically for AHK-Cu binding to Wnt pathway components remains to be established.

Copper Delivery

Like its parent compound GHK-Cu, AHK-Cu serves as a copper delivery vehicle to cells and tissues [4][5]. Copper is an essential cofactor for lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular respiration). This copper-shuttling function contributes to the broader tissue-supportive effects of the peptide.

Dose-Response Characteristics

An important observation from the Pyo et al. study is that AHK-Cu exhibited a bell-shaped dose-response curve -- stimulatory at low concentrations (10^-12 to 10^-9 M) but inhibitory at higher concentrations [1]. This biphasic response pattern is common among growth factors and growth factor-mimetic peptides and has important implications for formulation: more is not necessarily better, and optimal activity requires precise concentration targeting.

3. Researched Applications

Hair Growth Stimulation

Evidence level: Preliminary (single in vitro/ex vivo study)

The primary researched application of AHK-Cu is stimulation of hair growth. The Pyo et al. (2007) study demonstrated hair follicle elongation and dermal papilla cell proliferation in vitro and ex vivo [1]. No clinical trials evaluating AHK-Cu as a standalone hair growth treatment have been published.

Androgenetic Alopecia (Theoretical)

Evidence level: Theoretical (mechanistic rationale)

AHK-Cu's dual mechanism of VEGF upregulation and TGF-beta1 suppression provides a strong theoretical basis for application in androgenetic alopecia [1][9]. TGF-beta1 is a central mediator of androgen-induced follicle miniaturization, and VEGF supports the perifollicular vasculature that maintains follicle health [8][9]. However, no clinical studies have tested AHK-Cu in AGA patients.

Scalp Health and Anti-Aging

Evidence level: Extrapolated from GHK-Cu data

Based on the established skin remodeling effects of the parent compound GHK-Cu [5][7], AHK-Cu may contribute to scalp health through ECM remodeling, collagen synthesis, and antioxidant support. However, specific studies on AHK-Cu for scalp anti-aging are not available.

Wound Healing (Theoretical)

Evidence level: Extrapolated from copper tripeptide family data

The copper tripeptide family has well-documented wound healing properties [3][12][14], and AHK-Cu's ability to stimulate fibroblast proliferation and VEGF production [1] suggests potential wound healing applications. No direct studies of AHK-Cu in wound models have been published.

4. Clinical Evidence Summary

The evidence base for AHK-Cu is substantially narrower than that for GHK-Cu and relies primarily on a single foundational study:

1. Single study foundation: The core evidence for AHK-Cu derives from one published paper (Pyo et al. 2007), which is well-designed and published in a peer-reviewed journal but has not been independently replicated [1].

2. No clinical trials: No human clinical trials evaluating AHK-Cu for hair growth or any other application have been published.

3. In vitro/ex vivo only: All data are from cell culture and isolated hair follicle organ culture systems, which do not fully replicate the complexity of in vivo hair biology.

4. No head-to-head comparison with GHK-Cu: While the structural relationship between AHK-Cu and GHK-Cu is well-defined, direct comparative efficacy studies have not been published.

Despite these limitations, the mechanistic data from the Pyo et al. study are compelling, particularly the dual VEGF/TGF-beta1 modulation and the anti-apoptotic effects at picomolar concentrations [1].

5. Dosing in Research

All dosing data for AHK-Cu derive from in vitro and ex vivo studies. No clinical dosing data exist.

Key dosing observations:

• Effective concentrations in vitro are remarkably low: 10^-12 to 10^-9 M (picomolar to nanomolar range) [1].
• Higher concentrations inhibited rather than promoted growth, indicating a bell-shaped dose-response curve [1].
• In cosmetic formulations, AHK-Cu is typically used at 50-500 ppm, though optimal topical concentrations for hair growth have not been established through clinical studies.
• The extremely low effective in vitro concentrations suggest that even low topical concentrations may achieve biologically relevant levels at the follicular level after skin penetration.

6. Safety and Side Effects

Available Safety Data

AHK-Cu has limited published safety data. No clinical safety studies have been conducted. Available information includes:

• In vitro cytotoxicity: The Pyo et al. study demonstrated that AHK-Cu at effective concentrations (10^-12 to 10^-9 M) did not exhibit cytotoxicity to dermal papilla cells or fibroblasts [1]. The anti-apoptotic effects (caspase-3 and PARP reduction) further support cell-protective rather than cell-damaging properties.

• Cosmetic use track record: As a commercially available cosmetic ingredient (Copper Tripeptide-3), AHK-Cu has been incorporated into topical products without published reports of serious adverse events.

• GHK-Cu safety extrapolation: The parent compound GHK-Cu has a well-established topical safety profile from clinical studies, with no serious adverse events reported [5][7]. Similar safety characteristics are expected for the closely related AHK-Cu.

Precautions

• Concentration sensitivity: The bell-shaped dose-response curve observed in vitro means that excessive concentrations may be counterproductive [1].
• Copper sensitivity: Individuals with copper metabolism disorders (Wilson disease, Menkes disease) should exercise caution with copper-containing formulations.
• No systemic data: No safety data exist for injectable or oral administration. All available data pertain to topical use.
• Pregnancy and lactation: No specific safety studies exist for these populations.

Comparison with GHK-Cu

| Property | AHK-Cu (Copper Tripeptide-3) | GHK-Cu (Copper Tripeptide-1) | |---|---|---| | Natural occurrence | Synthetic | Natural (human plasma) | | Primary target | Hair follicle / dermal papilla | Skin / wound healing | | Clinical data | None (in vitro only) | Multiple controlled trials | | INCI registration | Yes | Yes | | Safety database | Limited | Extensive |

7. Regulatory Status

• INCI Name: Copper Tripeptide-3
• Classification: Cosmetic ingredient, not a pharmaceutical
• FDA: Not approved as a drug for any indication. As a cosmetic ingredient, it is not subject to pre-market drug approval.
• EU: Permitted in cosmetic formulations under EC Cosmetics Regulation 1223/2009.
• No drug approval: AHK-Cu has not received pharmaceutical approval for hair loss treatment or any other condition in any regulatory jurisdiction.
• Raw material availability: Available from multiple peptide synthesis suppliers as a cosmetic-grade raw ingredient.

8. Pharmacokinetics

AHK-Cu pharmacokinetics are understood primarily through its physicochemical properties and by analogy with the parent compound GHK-Cu, as no formal pharmacokinetic studies of AHK-Cu have been published [1][5].

Copper binding and release. AHK-Cu, like GHK-Cu, chelates copper(II) ions through coordination with the histidine imidazole nitrogen, the lysine amino group, and the N-terminal amine. Upon application to biological tissues, the copper ion is released to copper-requiring enzymes (lysyl oxidase, SOD, cytochrome c oxidase) and the free AHK peptide exerts its signaling effects on dermal papilla cells and fibroblasts [1][4][5]. The rate of copper release from AHK-Cu in the skin microenvironment has not been directly measured, but is expected to be governed by competitive chelation by intracellular copper-binding proteins such as metallothionein and albumin.

Topical penetration. AHK-Cu has a molecular weight of approximately 418 Da (with copper), which is below the 500 Da threshold generally considered favorable for passive skin penetration. When formulated in topical serums and lotions at concentrations of 50-500 ppm, AHK-Cu is expected to penetrate the stratum corneum and reach the dermis and hair follicle structures. The alanine substitution (replacing the smaller glycine in GHK-Cu) introduces a slight increase in hydrophobicity due to the additional methyl group, which may modestly enhance skin penetration relative to GHK-Cu, though this has not been directly measured.

Stability in formulation. The copper-peptide complex provides enhanced stability compared to the free peptide, as copper coordination protects the histidine-lysine chelation site from peptidase cleavage. AHK-Cu is compatible with a range of cosmetic formulation bases (aqueous, emulsion), though it should be protected from strong chelating agents (EDTA, citric acid at high concentrations) that could compete for copper binding.

Systemic absorption. No data exist on systemic absorption of AHK-Cu from topical application. Given its intended use at low concentrations in topical formulations and its rapid metabolism by tissue peptidases, significant systemic exposure is unlikely. No drug-drug interaction concerns have been identified.

Comparison with GHK-Cu pharmacokinetics. GHK-Cu occurs naturally in human plasma at measurable concentrations (approximately 200 ng/mL at age 20, declining with age) [4][5]. AHK-Cu is a synthetic compound not found endogenously, so there are no physiological reference levels. The slightly larger size of AHK (due to the alanine methyl group) and the absence of natural production means that AHK-Cu's tissue distribution profile may differ from GHK-Cu, particularly regarding receptor interactions and cellular uptake kinetics.

9. Dose-Response Relationships

The dose-response profile of AHK-Cu is defined by the landmark Pyo et al. (2007) study, which revealed a distinctive biphasic (bell-shaped) curve with important implications for formulation [1].

Hair follicle elongation. AHK-Cu stimulated elongation of isolated human hair follicles at concentrations from 10^-12 M (picomolar) to 10^-9 M (nanomolar). Maximal stimulatory activity was observed within this range. At concentrations above 10^-9 M, the stimulatory effect diminished, and at micromolar concentrations, inhibitory effects were observed [1]. This bell-shaped dose-response curve indicates that AHK-Cu operates within an optimal concentration window, and exceeding this window is counterproductive.

Dermal papilla cell proliferation. DPC proliferation followed the same bell-shaped pattern: stimulation at picomolar to nanomolar concentrations, inhibition at higher concentrations [1]. The picomolar effective range is remarkably potent and suggests that AHK-Cu operates through a specific receptor-mediated or signaling pathway mechanism rather than a nonspecific physicochemical effect.

VEGF production. VEGF secretion by dermal fibroblasts was increased by AHK-Cu in a concentration-dependent manner within the effective range [1]. The VEGF dose-response did not show the same bell-shaped inhibition at higher concentrations, suggesting that the VEGF-stimulating mechanism may be partially distinct from the direct growth-stimulatory pathway.

TGF-beta1 suppression. Reduced TGF-beta1 secretion was observed across the effective concentration range, with the degree of suppression following the same picomolar-to-nanomolar pattern as other endpoints [1].

Anti-apoptotic dose-response. The 42.7% reduction in caspase-3 and 77.5% reduction in PARP cleavage were measured at effective concentrations within the picomolar-to-nanomolar range [1]. These represent large-magnitude effects, particularly the PARP reduction, indicating potent anti-apoptotic activity at the same concentrations that stimulate proliferation.

Implications for topical formulation. The bell-shaped dose-response has critical practical implications: cosmetic formulations should aim to deliver AHK-Cu to hair follicles at picomolar-to-nanomolar concentrations rather than maximizing concentration. The typical cosmetic formulation range of 50-500 ppm (parts per million) delivers far higher concentrations to the surface than are needed at the follicular level, which is appropriate given that only a fraction of the applied compound penetrates to the target tissue.

10. Comparative Effectiveness

AHK-Cu vs. GHK-Cu (Copper Tripeptide-1)

AHK-Cu and GHK-Cu differ by a single amino acid (alanine vs. glycine at position 1), yet this minimal structural change produces measurably different biological activities [1][4][5]. The Pyo et al. (2007) study directly compared AHK-Cu with GHK-Cu for hair follicle elongation and dermal papilla cell effects, though specific comparative data between the two compounds within that study were not fully tabulated for all endpoints [1]. AHK-Cu appears to have enhanced specificity for hair follicle-related targets (DPC proliferation, VEGF/TGF-beta1 modulation) compared to GHK-Cu, which has broader tissue repair and skin remodeling activity [4][5]. GHK-Cu has a substantially larger evidence base including multiple clinical trials for skin rejuvenation and wound healing, while AHK-Cu evidence is limited to a single in vitro/ex vivo study. For hair growth applications, AHK-Cu's targeted mechanism may offer advantages; for general skin anti-aging, GHK-Cu remains the better-supported option.

AHK-Cu vs. Minoxidil

Minoxidil and AHK-Cu share the VEGF-upregulation mechanism [8]. Minoxidil promotes hair growth through VEGF-mediated perifollicular angiogenesis, potassium channel opening, and direct stimulation of dermal papilla cells [8][15]. AHK-Cu acts through DPC proliferation, VEGF upregulation, TGF-beta1 suppression, and anti-apoptotic protection -- a broader mechanistic profile [1]. No clinical comparison exists. Minoxidil has decades of clinical trial data and FDA approval, while AHK-Cu has only in vitro/ex vivo evidence. The two agents have complementary mechanisms and could theoretically be combined.

AHK-Cu vs. Biotinoyl Tripeptide-1

These two peptide-based hair ingredients act through distinct mechanisms: AHK-Cu primarily targets dermal papilla cells and the mesenchymal compartment of the hair follicle (VEGF, TGF-beta1, anti-apoptosis), while biotinoyl tripeptide-1 primarily targets keratinocytes and the epithelial compartment (keratinocyte proliferation, laminin-5, collagen IV). This complementarity makes them suitable for combination in multi-ingredient hair care formulations. AHK-Cu operates at picomolar-to-nanomolar concentrations with a bell-shaped dose-response, while biotinoyl tripeptide-1 shows efficacy at 2-5 ppm in ex vivo models.

| Feature | AHK-Cu | GHK-Cu | Minoxidil (5%) | |---|---|---|---| | Primary target cells | Dermal papilla cells | Fibroblasts, keratinocytes | DPC, vascular endothelium | | VEGF stimulation | Yes | Not specifically shown | Yes | | TGF-beta1 suppression | Yes | Not shown | Not directly | | Anti-apoptotic | Yes (caspase-3 -42.7%, PARP -77.5%) | Not specifically shown | Not shown | | Effective concentration | Picomolar-nanomolar | Nanomolar-micromolar | Millimolar (topical) | | Clinical evidence | None (in vitro only) | Multiple RCTs (skin) | Extensive RCTs (FDA-approved) | | Natural occurrence | Synthetic | Endogenous (human plasma) | Synthetic drug |

11. Enhanced Safety Profile

AHK-Cu has limited but favorable available safety data, with additional reassurance derived from the extensive safety record of the structurally related parent compound GHK-Cu [1][5][7].

In vitro cytotoxicity. At effective concentrations (10^-12 to 10^-9 M), AHK-Cu demonstrated no cytotoxicity to dermal papilla cells or dermal fibroblasts [1]. The anti-apoptotic effects (caspase-3 and PARP reduction) indicate a cell-protective rather than cell-damaging profile at therapeutic concentrations.

Bell-shaped dose-response as safety feature. The inhibitory effect of AHK-Cu at concentrations above the optimal range may serve as a built-in safety mechanism, preventing excessive stimulation even when higher concentrations are applied topically [1]. This self-limiting pharmacological profile reduces the risk of over-stimulation.

GHK-Cu safety extrapolation. The parent compound GHK-Cu has an extensive topical safety record from clinical trials involving hundreds of subjects with no serious adverse events [5][7]. As a structural analog differing by only a single methyl group, AHK-Cu is expected to share GHK-Cu's favorable safety profile, though independent confirmation through dedicated safety studies would strengthen this inference.

Cosmetic use track record. AHK-Cu (Copper Tripeptide-3) has been commercially available as a cosmetic ingredient for several years, with incorporation into topical hair growth and scalp care products. No published reports of serious adverse events from cosmetic use have emerged.

Copper safety. As with all copper-containing peptides, AHK-Cu delivers copper(II) ions to tissues. At the low concentrations used in cosmetic formulations (50-500 ppm), the copper load is minimal and unlikely to cause copper toxicity. Individuals with Wilson disease or other copper metabolism disorders should exercise caution with any copper-containing formulation [5].

Concentration sensitivity. The bell-shaped dose-response curve means that excessive formulation concentrations could theoretically reduce efficacy rather than enhance it [1]. While this is primarily an efficacy concern rather than a safety concern, it underscores the importance of using AHK-Cu at appropriate concentrations.

No systemic or reproductive safety data. AHK-Cu has no published systemic safety data, and no studies have evaluated safety during pregnancy, lactation, or in pediatric populations. The compound's very low effective concentration range and topical route of administration suggest minimal systemic exposure.

12. Related Peptides

See also: GHK-Cu, GHK, Biotinoyl Tripeptide-1, Acetyl Tetrapeptide-3

• GHK-Cu -- The naturally occurring parent compound (Copper Tripeptide-1) from which AHK-Cu is derived. GHK-Cu has a substantially broader evidence base including clinical trials for skin remodeling and wound healing. Differs by having glycine rather than alanine at position 1.

• GHK -- The copper-free form of the parent tripeptide. GHK modulates over 4,000 genes and serves as the foundation for multiple copper tripeptide variants including AHK-Cu.

• Biotinoyl Tripeptide-1 -- A biotin-conjugated GHK derivative designed for hair growth through keratinocyte proliferation and laminin/collagen IV synthesis. Complementary mechanism to AHK-Cu's dermal papilla cell stimulation.

• Acetyl Tetrapeptide-3 -- The peptide component of Capixyl, a tetrapeptide (KGHK) that stimulates collagen III and laminin production in dermal papilla cells for hair follicle anchoring. Shares the His-Lys motif with AHK-Cu.

13. References

1. [1] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. DOI PubMed
2. [2] Pickart L, Thaler MM. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. DOI PubMed
3. [3] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. DOI PubMed
4. [4] Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. DOI PubMed
5. [5] Pickart L, Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. DOI PubMed
6. [6] Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC. (2009). Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research. DOI PubMed
7. [7] Leyden JJ, Stevens T, Finkey MB, Barkovic S. (2002). Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting. PubMed
8. [8] Messenger AG, Rundegren J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. DOI PubMed
9. [9] Inui S, Itami S. (2011). Androgen actions on the human hair follicle: perspectives. Experimental Dermatology. DOI PubMed
10. [10] Kishimoto J, Burgeson RE, Morgan BA. (2000). Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes and Development. DOI PubMed
11. [11] Kwack MH, Sung YK, Chung EJ, Im SU, Ahn JS, Kim MK, Kim JC. (2008). Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. Journal of Investigative Dermatology. DOI PubMed
12. [12] Canapp SO, Farese JP, Schultz GS, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. DOI PubMed
13. [13] Pollard JD, Quan S, Kang T, Koch RJ. (2005). Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Archives of Facial Plastic Surgery. DOI PubMed
14. [14] Maquart FX, Bellon G, Chaqour B, Wegrowski J, Pira S, Gillery P, Monboisse JC, Borel JP. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation. DOI PubMed
15. [15] Suchonwanit P, Thammarucha S, Leerunyakul K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. DOI PubMed
16. [16] Philp D, Nguyen M, Scheremeta B, et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. DOI PubMed
17. [17] Kumar A, et al. (2025). Topical alternatives for hair loss: beyond the conventional. Clinical, Cosmetic and Investigational Dermatology. PubMed
18. [18] Dhariwala MY, Ravikumar P. (2019). An overview of herbal alternatives in androgenetic alopecia. Journal of Cosmetic Dermatology. DOI PubMed